A Randomized, Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With Measles, Mumps, and Rubella Combined Live Attenuated Vaccine/ Encephalitis Live Attenuated Vaccine
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Hand, Foot and Mouth Disease
- Sponsor
- Sinovac Biotech Co., Ltd
- Enrollment
- 372
- Locations
- 1
- Primary Endpoint
- The seroconversion rates（SCR） of the EV71 neutralizing antibody 30 days after two dose of EV71 vaccines
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
The purpose of this study is to evaluate the safety and immunogenicity of concomitant administration of EV71 vaccine with measles mumps, and rubella combined live attenuated vaccine/ encephalitis live attenuated vaccine.
Detailed Description
This study is an open-label, single-center, randomized, comparative phase IV clinical trial. The purpose of this study is to evaluate the safety andimmunogenicity of concomitant administration of EV71 vaccine manufactured by Sinovac (Beijing) Vaccine Technology Co., Ltd. with measles mumps, and rubella combined live attenuated vaccine/ encephalitis live attenuated vaccine. 360 healthy infants of 8 months old as participants are randomly assigned into three experimental groups in the ratio 1:1:1. The group I receive EV71 Vaccine (first dose)\&measles mumps, and rubella combined live attenuated vaccine on day 0 and EV71 vaccine (second dose)\&encephalitis live attenuated vaccine on day 30. The group II receive measles mumps, and rubella combined live attenuated vaccine on day 0 and encephalitis live attenuated vaccine on day 30. The group III receive the first and second dose of EV71 Vaccine on day 0 and day 30 respectively.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Healthy volunteer aged ≥ 8 months;
- •Proven legal identity;
- •Guardians of the participants should be capable of understanding the written consent form, and such form should be signed before the infant being included into this study.
Exclusion Criteria
- •Prior vaccination with EV71 vaccine;
- •Prior vaccination with MMR vaccine or vaccine including mumps or measles or mumps or rubella vaccine components;
- •Prior vaccination with Encephalitis B vaccine；
- •Cannot be vaccinated with both arms at the same time；
- •History of hand，foot and mouth disease;
- •History of measles or mumps or rubella or encephalitis B；
- •Allergy to gentamicin; history of allergy to any vaccine or vaccine ingredient, or serious adverse reaction(s) to vaccination, such as urticaria,difficulty in breathing, angioneurotic edema, pain, etc;
- •Congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc;
- •Autoimmune diseases or immunodeficiency/immunosuppression;
- •Severe neurological disorders (epilepsy, convulsions or convulsions) or psychosis;
Outcomes
Primary Outcomes
The seroconversion rates（SCR） of the EV71 neutralizing antibody 30 days after two dose of EV71 vaccines
Time Frame: 30 days after two dose of EV71 vaccines
Immunogenicity indicator
Secondary Outcomes
- The seroconversion rates（SCR） of the Measles IgG antibody，Rubella 30 IgG antibody and Mumps IgG antibody 60 days after one dose of MMR vaccine(60 days after one dose of MMR vaccine)
- The seroconversion rates（SCR） of the Japanese encephalitis neutralizing antibody 30 days after one dose of Encephalitis B vaccine(30 days after one dose of Encephalitis B vaccine)
- Measles IgG antibody，Rubella 30 IgG antibody and Mumps IgG antibody positive rate 60 days after one dose of MMR vaccine(60 days after one dose of MMR vaccine)
- EV71 neutralizing antibody positive rate 30 days of two dose of EV71 vaccines(30 days after two dose of EV71 vaccines)
- The Geometric mean titer (GMT) of the EV71 neutralizing antibody 30 days of two dose of EV71 vaccines(30 days after two dose of EV71 vaccines)
- The Geometric mean titer (GMT) of Measles IgG antibody，Rubella 30 IgG antibody and Mumps IgG antibody 60 days after one dose of MMR vaccine(60 days after one dose of MMR vaccine)
- The Geometric mean titer (GMT) of Japanese encephalitis neutralizing antibody 30 days after one dose of Encephalitis B vaccine(30 days after one dose of Encephalitis B vaccine)
- Incidence of serious adverse events (SAEs) during the period of safety monitoring(0-30 days after each dose)
- The Japanese encephalitis neutralizing antibody positive rate 30 days after one dose of Encephalitis B vaccine(30 days after one dose of Encephalitis B vaccine)
- Incidence of solicited local or systemic adverse events within 7 days or 14 days after each dose(7 days or 14 days after each dose of injection)
- The incidences of adverse reactions after each does(0-30 days after each dose)